BioMarin Gains on Prospects for Experimental Cancer Drug

BioMarin Pharmaceutical Inc., a maker of drugs for rare diseases, rose the most in more than six months ahead of a medical conference where the company plans to publish data on its experimental cancer therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.